Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 519,446	$ 315,382
Available for sale securities	50,875	25,130
Accrued interest receivable	348	374
Accounts receivable, net of allowances of approximately $17.7 million and $18.1 million at December 31, 2012 and 2011	85,893	74,559
Inventory	76,355	45,145
Deferred tax assets	13,881	9,395
Prepaid expenses and other current assets	9,577	11,738
Total current assets	756,375	481,723
Fixed assets, net	16,100	17,979
Intangible assets, net	119,576	87,329
Goodwill	14,671	14,671
Restricted cash	1,571	4,714
Deferred tax assets	46,625	78,441
Other assets	17,264	7,790
Total assets	972,182	692,647
Current liabilities:
Accounts payable	25,378	6,587
Accrued expenses	107,453	147,382
Deferred revenue	2,375	666
Total current liabilities	135,206	154,635
Contingent purchase price	18,971	20,431
Convertible senior notes (due 2017)	226,109	0
Other liabilities	5,674	5,939
Total liabilities	385,960	181,005
Stockholders' equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $.001 par value per share, 125,000,000 shares authorized; 56,153,140 issued and 53,960,158 outstanding at December 31, 2012 and 54,313,107 issued and outstanding at December 31, 2011	56	54
Additional paid-in capital	697,427	623,801
Treasury stock, at cost; 2,192,982 and 0 shares at December 31, 2012 and December 31, 2011, respectively	(50,000)	0
Accumulated deficit	(60,411)	(111,665)
Accumulated other comprehensive (loss)	(766)	(548)
Total The Medicines Company stockholders’ equity	586,306	511,642
Non-controlling interest in joint venture	(84)	0
Total stockholders’ equity	586,222	511,642
Total liabilities and stockholders’ equity	$ 972,182	$ 692,647